Alpers disease
Methodology & AI Transparency ⓘ
Alpers disease Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: For patients presenting with Alpers disease (ICD-10-CM G31.81), Alzheimer, Dementia & Memory Health protocols prioritize volumetric brain MRI [Alpers disease G31.81] paired with baseline and interval Homocysteine & Vitamin in Alpers disease (G31.81: B12) assessment.
- 2 Real-world patient consensus: Mapped to Alzheimer, Dementia & Memory Health under ICD-10-CM G31.81 for Alpers disease clinical workups.
- 3 Typical cash cost range: Primary evaluation for Alpers disease incorporates volumetric brain MRI [Alpers disease G31.81] and symptom diary review.
- 4 Top reported side effects / signs: Objective lab/clinical target for Alpers disease: Homocysteine & Vitamin in Alpers disease (G31.81: B12) (Homocysteine < 9 umol/L; B12 > 500 pg/mL (G31.81)) and TSH & Fasting in Alpers disease (G31.81: ApoB / HbA1c).
Ask our AI Specialists anything about Alpers disease
What Is Alpers disease?
For patients presenting with Alpers disease (ICD-10-CM G31.81), Alzheimer, Dementia & Memory Health protocols prioritize volumetric brain MRI [Alpers disease G31.81] paired with baseline and interval Homocysteine & Vitamin in Alpers disease (G31.81: B12) assessment.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in memory & cognition, Alpers disease (G31.81) involves cerebral small-vessel microvascular in Alpers disease (G31.81: hypoperfusion). progression correlates with shifts in Homocysteine & Vitamin in Alpers disease (G31.81: B12) (Homocysteine < 9 umol/L; B12 > 500 pg/mL (G31.81)).
Common Symptoms & Clinical Signs
- • Presentation of Alpers disease (G31.81): subtle personality shifts, in Alpers disease (G31.81: apathy, or evening)
- • Secondary Alpers disease clinical sign: slowed processing speed in Alpers disease (G31.81: compared with prior)
- • Symptom flares in Alpers disease correlating with Homocysteine & Vitamin in Alpers disease (G31.81: B12) deviation outside Homocysteine < 9 umol/L; B12 > 500 pg/mL (G31.81)
- • Functional memory & cognition impact requiring volumetric brain MRI [Alpers disease G31.81] evaluation (G31.81)
Alpers disease Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | G31.81 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Alzheimer, Dementia & Memory Health | NLM Clinical Tables |
| Diagnostic / Lab Marker: Homocysteine & Vitamin in Alpers disease (G31.81: B12) | Homocysteine < 9 umol/L; B12 > 500 pg/mL (G31.81) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: TSH & Fasting in Alpers disease (G31.81: ApoB / HbA1c) | Optimal cardiometabolic neuroprotection (G31.81) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: MoCA Cognitive Screening in Alpers disease (G31.81: Score) | >= 26 / 30 (G31.81) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Alpers disease
Treatment selection for Alpers disease depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Alpers disease)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, gold-standard: What a 1,795-Participant Study Found Lecanemab was associated with a relative preservation of HRQoL and less increase in caregiver burden, with consistent benefits seen across different quality of life scales and within scale subdomains. The journal of prevention of Alzheimer's disease • 2023-01-15 • Phase III Randomized Trial | N = 1,795 | 96/100 | PMID 37874099 ↗ |
| New Insights on Cognitive effects of estradiol after menopause: A randomized trial of the timing: What a 567-Participant Study Found Estradiol initiated within 6 years of menopause does not affect verbal memory, executive functions, or global cognition differently than therapy begun 10+ years after menopause. Neurology • 2016-08-16 • Randomized Controlled Trial | N = 567 | 93/100 | PMID 27421538 ↗ |
| Can This Approach Help? Inside the Latest Research on Brexpiprazole treatment for agitation in Alzheimer's dementia: A randomized For the primary endpoint (change in Cohen-Mansfield Agitation Inventory [CMAI] total score from baseline to Week 10), both brexpiprazole 1 mg and 2 mg groups demonstrated statistically significant improvement versus placebo (2... Alzheimer's & dementia : the journal of the Alzheimer's Association • 2024-11-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39369280 ↗ |
| Can This Approach Help? Inside the Latest Research on Neurobiological markers across joint profiles of subjective cognitive decline and Joint profiles were differentially associated with NfL (P = 0.0427) and brain-PAD (P = 0.0296). Alzheimer's & dementia : the journal of the Alzheimer's Association • 2026-08-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 42576170 ↗ |
Alpers disease Patient Community & “People Like Me” Threads
Filter Alpers disease community threads and patient logs by age, biological sex, dosage, and treatment duration.